Inhibrx Biosciences (INBX) EBT Margin (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of EBT Margin data on file, last reported at 2204.0% in Q2 2025.

• On a quarterly basis, EBT Margin fell 186021700.0% year-over-year to 2204.0% in Q2 2025; TTM through Dec 2025 was 10003.79%, a 10201982.0% decrease from a year earlier, with the FY2025 full-year figure at 10773.31%, down 85456031.0% from the prior year.
• EBT Margin for Q2 2025 stood at 2204.0%, up from 47865.0% in the prior quarter.
• Over the last five years, EBT Margin for INBX reached as high as 1858013.0% in Q2 2024 and fell as low as 156823.33% in Q2 2023.
• Historically, EBT Margin has averaged 266995.57% across 3 years, with a median of 24573.63% in 2023.
• Across the five-year window, EBT Margin surged 201483633 bps in 2024 and tumbled 186021700 bps in 2025, its largest moves.
• Year by year, EBT Margin stood at 5628.76% in 2023, then sank by 750 bps to 47865.0% in 2024, then surged by 95 bps to 2204.0% in 2025.
• Per Business Quant data, the three most recent EBT Margin figures were 2204.0% in Q2 2025, 47865.0% in Q4 2024, and 1858013.0% in Q2 2024.